As children of parents who had cancer we have experienced how devastating the disease can be. We both shifted how we utilize our life for our work to be dedicated to improving the standard of care for patients. DNKO LLC is a collaboration between David Needham PhD, DSc and Katherine Onk. 

Vision
Our overall DNKO vision is that brain cancer patients will have access to a clinically more effective treatment that prioritizes patients before profits and, when tested, may even be curative for the right sized and LITT-heatable tumors.

Mission
Our current DNKO mission is to bring existing and proven technology, specifically Laser Interstitial Thermal Therapy (LITT) and David's invention, the Low Temperature Sensitive Liposomal Doxorubicin (LTSL-Dox) to the brain cancer community, uniting like-minded clinicians to evaluate it, test it and (if it shows promise) bring it as soon as possible to their patients. 

Biotechnology

Health Care

Life Sciences

Therapeutics

DNKO

DNKO's headquarters in Remote, United States

Kate Hammer

David Needham

This department provides strategic direction and overarching leadership for the organization.

DNKO

Org chart

Teams

Executive Leadership

Offices

DNKO

Org chart

Teams

Executive Leadership

Offices

Related companies